Efficacy and immunologic effects of extracorporeal photopheresis plus interleukin-2 in chronic graft-versus-host disease.

Adult Aged CD4-Positive T-Lymphocytes CD8-Positive T-Lymphocytes Cell Proliferation / drug effects Chronic Disease Combined Modality Therapy / methods Female Graft vs Host Disease / therapy Humans Interleukin-2 / immunology Killer Cells, Natural / cytology Male Middle Aged Photopheresis / methods T-Lymphocytes, Regulatory / cytology Time Factors Treatment Outcome

Journal

Blood advances
ISSN: 2473-9537
Titre abrégé: Blood Adv
Pays: United States
ID NLM: 101698425

Informations de publication

Date de publication:
09 04 2019
Historique:
received: 25 11 2018
accepted: 23 02 2019
entrez: 3 4 2019
pubmed: 3 4 2019
medline: 24 7 2020
Statut: ppublish

Résumé

Chronic graft-versus-host disease (cGVHD) affects >50% of hematopoietic stem cell transplant patients. Extracorporeal photopheresis (ECP), an immunomodulatory therapy, provides clinical benefit in steroid-refractory (SR) cGVHD, possibly via regulatory T (T

Identifiants

DOI: 10.1182/bloodadvances.2018029124 PMID: 30936057 PMC: PMC6457231
pubmed: 30936057
pii: bloodadvances.2018029124
doi: 10.1182/bloodadvances.2018029124
pmc: PMC6457231
doi:

Substances chimiques

Interleukin-2 0

Banques de données

ClinicalTrials.gov
['NCT02340676']

Types de publication

Clinical Trial, Phase II Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

969-979

Subventions

Organisme : NHLBI NIH HHS
ID : R01 HL118979
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183560
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA183559
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA142106
Pays : United States
Organisme : NIAID NIH HHS
ID : P01 AI056299
Pays : United States
Organisme : NCI NIH HHS
ID : P01 CA229092
Pays : United States

Informations de copyright

© 2019 by The American Society of Hematology.

Références

J Immunol. 2005 May 15;174(10):5968-76
pubmed: 15879089
Blood. 2014 Jul 17;124(3):374-84
pubmed: 24914139
Transplantation. 2009 May 15;87(9):1422-5
pubmed: 19424046
Br J Haematol. 2004 Sep;126(5):697-703
pubmed: 15327522
Transplantation. 2009 Aug 15;88(3):411-6
pubmed: 19667946
JCI Insight. 2016 Nov 3;1(18):e89278
pubmed: 27812545
Blood. 2008 Aug 15;112(4):1515-21
pubmed: 18411417
Biol Blood Marrow Transplant. 2010 Dec;16(12):1611-28
pubmed: 20601036
Blood. 2011 Oct 13;118(15):4242-9
pubmed: 21791424
Clin Immunol. 2008 May;127(2):151-7
pubmed: 18299252
Blood. 2006 Sep 1;108(5):1571-9
pubmed: 16645171
J Invest Dermatol. 1996 Aug;107(2):235-42
pubmed: 8757769
Photochem Photobiol. 1997 Jan;65(1):177-80
pubmed: 9066299
Nat Med. 2003 Sep;9(9):1144-50
pubmed: 12925844
Blood. 2001 Sep 1;98(5):1622-5
pubmed: 11520818
Blood. 2005 Oct 15;106(8):2903-11
pubmed: 15972448
Nat Med. 2005 Nov;11(11):1238-43
pubmed: 16227988
Blood. 2016 Jul 7;128(1):130-7
pubmed: 27073224
J Heart Lung Transplant. 2008 Jun;27(6):616-22
pubmed: 18503960
Nat Rev Immunol. 2010 Jul;10(7):490-500
pubmed: 20559327
Ann Rheum Dis. 2006 Nov;65(11):1512-7
pubmed: 16606650
Blood. 1998 Nov 1;92(9):3098-104
pubmed: 9787144
Transplantation. 2005 Apr 15;79(7):846-50
pubmed: 15818329
J Clin Invest. 2010 May;120(5):1479-93
pubmed: 20389017
J Exp Med. 2002 Aug 5;196(3):389-99
pubmed: 12163567
Leuk Lymphoma. 2016 Feb;57(2):376-384
pubmed: 26059058
J Allergy Clin Immunol. 2004 Dec;114(6):1425-33
pubmed: 15577848
Transfus Apher Sci. 2015 Apr;52(2):157-61
pubmed: 25716169
Transplantation. 2007 Jul 15;84(1):31-9
pubmed: 17627234
Blood. 2017 Jan 5;129(1):22-29
pubmed: 27821505
Transplantation. 2007 May 27;83(10):1393-6
pubmed: 17519793
Transplant Proc. 2007 Jan-Feb;39(1):213-7
pubmed: 17275508
N Engl J Med. 2011 Dec 1;365(22):2055-66
pubmed: 22129252
Nat Immunol. 2016 Nov;17(11):1322-1333
pubmed: 27595233
Blood. 2006 Mar 15;107(6):2409-14
pubmed: 16304057
Blood. 2008 Oct 1;112(7):2667-74
pubmed: 18621929
J Exp Med. 2002 Sep 16;196(6):851-7
pubmed: 12235217
Nat Immunol. 2005 Nov;6(11):1142-51
pubmed: 16227984
Blood. 2006 Apr 15;107(8):3074-80
pubmed: 16368882
Biol Blood Marrow Transplant. 2006 Mar;12(3):252-66
pubmed: 16503494
Blood. 2002 May 15;99(10):3493-9
pubmed: 11986199
Br J Haematol. 2017 Apr;177(2):287-310
pubmed: 28220931
Bone Marrow Transplant. 2005 Jun;35(12):1187-93
pubmed: 15852025
J Clin Apher. 2006 Oct;21(3):181-7
pubmed: 16607632
Blood. 2014 Dec 4;124(24):3572-6
pubmed: 25323825
Transfusion. 2012 Sep;52(9):2007-15
pubmed: 22320219
Transfus Apher Sci. 2012 Apr;46(2):181-8
pubmed: 22115608

Auteurs

Roger Belizaire (R)

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Haesook T Kim (HT)

Department of Biostatistics and Computational Biology and.

Samuel J Poryanda (SJ)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Nikola V Mirkovic (NV)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Evelyn Hipolito (E)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

William J Savage (WJ)

Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.

Carol G Reynolds (CG)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Marie J Fields (MJ)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Jennifer Whangbo (J)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Tomohiro Kubo (T)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Sarah Nikiforow (S)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Edwin P Alyea (EP)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Philippe Armand (P)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Corey S Cutler (CS)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Vincent T Ho (VT)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Bruce R Blazar (BR)

Masonic Cancer Center and.
Division of Blood and Marrow Transplantation, Department of Pediatrics, University of Minnesota, Minneapolis, MN.

Joseph H Antin (JH)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Jerome Ritz (J)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.
ORCID: 0000-0001-5526-4669

Robert J Soiffer (RJ)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

John Koreth (J)

Division of Hematologic Malignancies, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; and.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Efficacy and immunologic effects of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Efficacy and immunologic effects of...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD4+ › Efficacy and immunologic effects of...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › Efficacy and immunologic effects of...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Efficacy and immunologic effects of...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Efficacy and immunologic effects of...
questionsmedicales.fr › Thérapeutique › Association thérapeutique › Efficacy and immunologic effects of...
questionsmedicales.fr › Maladies du système immunitaire › Maladie du greffon contre l'hôte › Efficacy and immunologic effects of...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Efficacy and immunologic effects of...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Lymphokines › Interleukine-2 › Efficacy and immunologic effects of...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Cellules tueuses naturelles › Efficacy and immunologic effects of...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Efficacy and immunologic effects of...
questionsmedicales.fr › Procédures de chirurgie opératoire › Circulation extracorporelle › Photophérèse › Efficacy and immunologic effects of...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T régulateurs › Efficacy and immunologic effects of...
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Efficacy and immunologic effects of...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Efficacy and immunologic effects of...